467 related articles for article (PubMed ID: 26679899)
1. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
2. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
[No Abstract] [Full Text] [Related]
3. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
4. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
5. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.
Zhong M; Tian W; Zhuge J; Zheng X; Huang T; Cai D; Zhang D; Yang XJ; Argani P; Fallon JT; Epstein JI
Am J Surg Pathol; 2015 Jan; 39(1):127-31. PubMed ID: 25118812
[TBL] [Abstract][Full Text] [Related]
6. Telomere shortening distinguishes inverted urothelial neoplasms.
Williamson SR; Zhang S; Lopez-Beltran A; Montironi R; Wang M; Cheng L
Histopathology; 2013 Mar; 62(4):595-601. PubMed ID: 23379729
[TBL] [Abstract][Full Text] [Related]
7. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
8. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
[TBL] [Abstract][Full Text] [Related]
11. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
12. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
[TBL] [Abstract][Full Text] [Related]
13.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
Cheng L; Zhang S; Wang M; Lopez-Beltran A
Hum Pathol; 2023 Mar; 133():56-75. PubMed ID: 35700749
[TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
18. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients.
Picozzi S; Casellato S; Bozzini G; Ratti D; Macchi A; Rubino B; Pace G; Carmignani L
Urol Oncol; 2013 Nov; 31(8):1584-90. PubMed ID: 22520573
[TBL] [Abstract][Full Text] [Related]
19. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
20. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
Günes C; Wezel F; Southgate J; Bolenz C
Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]